title: Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party.
abstract: The study set out to determine the rate of long-term survivors (LTS) in patients treated with platinum-containing chemotherapy for advanced non-small cell lung cancer (NSCLC), to identify prognostic factors predicting long-term survival (> or = 2 years) and to report the LTS natural history. Eligible patients with advanced NSCLC treated by chemotherapy in one of seven trials conducted by the European Lung Cancer Working Party from December 1980 to August 1991 were included. All patients received cisplatin and/or carboplatin. Of these, 1052 patients were eligible and 24 variables were analysed as potential prognostic factors. Actuarial 2-year and 5-year survival rates were, respectively, 7.4 and 1.8%. All patients surviving for > or = 5 years had limited disease and were treated by complementary chest irradiation and/or surgery. Univariate prognostic factor analysis for LTS identified as significant no major weight loss, limited disease, no liver metastases, normal white blood cells and neutrophils and normal lactic dehydrogenase levels. By multivariate analysis, the only significant factor was limited disease. Objective response to chemotherapy was also found to be, as disease extent, a highly significant predictor for LTS. Thus, the two best prognostic factors for LTS were non-metastatic disease and response to chemotherapy.
authors.affiliation: Service de Médecine, Institute Jules Bordet, Bruxelles, Belgium.
authors.forename: J P
authors.initials: JP
authors.lastname: Sculier
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: P
authors.initials: P
authors.lastname: Libert
authors.forename: G
authors.initials: G
authors.lastname: Bureau
authors.forename: G
authors.initials: G
authors.lastname: Dabouis
authors.forename: J
authors.initials: J
authors.lastname: Thiriaux
authors.forename: J
authors.initials: J
authors.lastname: Michel
authors.forename: O
authors.initials: O
authors.lastname: Van Cutsem
authors.forename: J
authors.initials: J
authors.lastname: Schmerber
authors.forename: V
authors.initials: V
authors.lastname: Giner
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality*; D002945:Cisplatin / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D002945:Cisplatin